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Abstract 
Background: Cutaneous leishmaniasis causes a high disease burden in Colombia, and 
available treatments present systemic toxicity, low patient compliance, contraindications, 
and high costs. 
Objective: To estimate the cost-effectiveness of thermotherapy versus Glucantime in 
patients with cutaneous leishmaniasis in Colombia. 
Methods: Cost-effectiveness study from an institutional perspective in 8,133 incident 
cases. Data on therapeutic efficacy and safety were included, calculating standard costs; the 
outcomes were disability adjusted life years (DALYs) and the number of patients cured. 
The information sources were the Colombian Public Health Surveillance System, disease 
burden studies, and one meta-analysis of controlled clinical trials. Incremental cost-
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effectiveness was determined, and uncertainty was evaluated with tornado diagrams and 
Monte Carlo simulations. 
Results: Thermotherapy would generate costs of US$ 501,621; the handling of adverse 
effects, US$ 29,224; and therapeutic failures, US$ 300,053. For Glucantime, these costs 
would be US$ 2,731,276, US$ 58,254, and US$ 406,298, respectively. With 
thermotherapy, the cost would be US$ 2,062 per DALY averted and US$ 69 per patient 
cured; with Glucantime, the cost would be US$ 4,241 per DALY averted and US$ 85 per 
patient cured. In Monte Carlo simulations, thermotherapy was the dominant strategy for 
DALYs averted in 67.9% of cases and highly cost-effective for patients cured in 72%. 
Conclusion: In Colombia, thermotherapy can be included as a cost-effective strategy for 
the management of cutaneous leishmaniasis. Its incorporation into clinical practice 
guidelines could represent savings of approximately US$ 10,488 per DALY averted and 
costs of US$ 116 per additional patient cured, compared to the use of Glucantime. These 
findings show the relevance of the incorporation of this treatment in our country and others 
with similar parasitological, clinical, and epidemiological patterns. 
Keywords: cost-effectiveness evaluation, cutaneous leishmaniasis, thermotherapy, sodium 
antimony gluconate, Colombia. 
JEL: D61, I18, I10 
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Introduction 
Leishmaniasis is a major public health disease – particularly in the vector-borne 
group – given that it is endemic in 98 countries and approximately 350 million people are at 
risk worldwide. According to the World Health Organization (WHO), its incidence ranges 
from 200,000 to 400,000 cases for visceral leishmaniasis and 700,000 to 1,200,000 for 
cutaneous leishmaniasis. The latter is distributed worldwide, predominating in the 
Americas, the Mediterranean region, and Asia. Approximately 70%-75% of the global 
incidence occurs in 10 countries: Colombia, Afghanistan, Algeria, Brazil, Costa Rica, 
Ethiopia, Iran, Peru, Sudan, and Syria (Von Stebut, 2015; Alvar, 2012). 
The disease presents a variety of forms, varying in severity from a cutaneous ulcer 
that heals spontaneously to a visceral disease. There are three main clinical forms of the 
disease: i) cutaneous (localized, and disseminated or diffuse), ii) mucocutaneous, and iii) 
visceral or kala-azar. The form is determined by the species of the infectious parasite and 
the immune status of the host. In general terms, it mainly affects the poorest populations, 
being associated with poor housing conditions and a lack of economic resources (Guerra, 
2015; de Vries, 2015; Ruoti, 2013). 
Although there are effective therapies for cutaneous leishmaniasis, first-line 
treatments (pentavalent antimonials) have limitations due to safety concerns and their cost-
effectiveness, causing adverse effects such as arthralgia, myalgia, respiratory disorders, and 
systemic toxicity. Adding to these concerns, these treatments are contraindicated in multiple 
groups of people such as pregnant women, and the cost of these drugs in Colombia is very 
high. These limitations have led to the need to investigate alternative treatments such as 
thermotherapy, which has shown favorable efficacy and safety results (Masmoudi, 2013; 
Cardona, 2015). 
Regarding this therapy, one meta-analysis of eight clinical trials evaluated 
thermotherapy in 622 patients and showed an efficacy of 73.2% (95% CI = 69.6-76.7); this 
meta-analysis compared thermotherapy to the use of pentavalent antimonials in 667 
infected patients and found a similar statistical efficacy (70.6% CI 95% = 67.1-74.1). In this 
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meta-analysis, there was a high heterogeneity in the findings, methodology of the studies, 
infecting species, and other parasitological and clinical characteristics that prevent the 
extrapolation of these results to Colombia (Cardona, 2015). 
Globally, despite the great number of studies on cutaneous leishmaniasis, the papers 
are mainly focused on clinical and preclinical aspects, epidemiological research on the 
magnitude and risks of the disease, and drug efficacy; systematic reviews have also been 
published on the quality of clinical trials in this disease (Olliaro, 2013), and research on 
health economics is scarce. In this regard, there is one systematic review of economic 
evaluations available that identifies, describes, classifies, and analyzes the scientific 
evidence related to the economic evaluation of the health technologies used in visceral 
leishmaniasis, concluding that the most common studies are based on cost-effectiveness 
analysis (Marinho, 2015). 
In addition to the above, scarce economic evaluations of cutaneous leishmaniasis 
have been found in the world scientific literature, after conducting a search of studies 
published during the 1980-2014 period in the MEDLINE-PubMed, MEDLINE-Ovid, 
ScienceDirect, SciELO, Health Technology Assessment, and NHS-Economic Evaluation 
databases and using the following search strategies: i) economic evaluation &leishmania, ii) 
costs &leishmania, iii) cost-effectiveness &leishmania, iv) cost-utility &leishmania, and v) 
cost-benefit &leishmania. Based on the above search strategy, five economic evaluations 
were found. One was an incomplete economic evaluation, in which the costs of laboratory 
tests, treatment, and hospitalization were determined (Dedet, 1991). In Kabul, Afghanistan, 
a cost-effectiveness evaluation was developed for the intralesional and intramuscular 
administration of antimonials, concluding that the cost with the standard treatment was US$ 
27 (95% CI = 20-36) per patient cured and US$ 1,200 (95% CI = 761-1827) per disability 
adjusted life year (DALY) averted (Reithinger, 2007). In Argentina, it was reported that the 
incremental cost-effectiveness ratio (ICER) was US$ 459 for early diagnosis per DALY 
averted and US$ 16,478 for insecticide prevention per DALY averted (Orellano, 2013). In 
Latin American countries, a simulation study on the cost-effectiveness of a potential 
vaccine for the disease was conducted (Bacon, 2013). Finally, a cost-effectiveness study of 
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the standard treatment was conducted in Colombia in 2004 during an outbreak (Vega, 
2007). 
In addition to the previous studies, a cost-effectiveness study was conducted in 
Colombia in 2014 for first-line treatments for infected elderly people, concluding that the 
most cost-effective treatment is based on pentavalent antimonials, compared to miltefosine, 
pentamidine, and no treatment (Niño, 2014). 
The above shows that, in Colombia and in the world literature in general, there is no 
comprehensive economic research comparing the cost-effectiveness of thermotherapy 
versus pentavalent antimonials in patients with cutaneous leishmaniasis. This research is 
extremely important to lead to a more efficient use of health system resources (particularly 
those destined for the control of vector diseases) and to generate evidence on the potential 
clinical, epidemiological, and economic benefits of incorporating this therapy into clinical 
practice guidelines and public health programs. This is even more important when we bear 
in mind that leishmaniasis represented 4.7% of the parasitic and vector-borne disease 
burden in the world in 2012, with 3,374,000 DALYs, and that in Colombia in 2000, it 
caused 1,356 DALYs (WHO, 2014). 
Consistent with the above, the aim of this study is to estimate the cost-effectiveness 
ratio of thermotherapy compared to Glucantime in patients with cutaneous leishmaniasis in 
Colombia. 
Materials and methods 
Type of study: Cost effectiveness analysis from an institutional perspective, using a 
decision tree. 
Components of the PICO T-R question: Population, Intervention, Comparator, 
Outcome; Time, and Resources. 
Population: Incident cases of cutaneous leishmaniasis diagnosed in Colombia during 
2015, which totaled 8,113 cases according to the National Public Health Surveillance 
System (National Institute of Health of Colombia, SIVIGILA, 2016). 
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Intervention: Application of local heat (thermotherapy) by radiofrequency at 50 °C 
for 30 seconds three times a week with ThermoMed® equipment from Thermosurgery Inc. 
(Phoenix, Arizona, USA). The application of thermotherapy begins with the establishment 
of asepsis in the lesion and infiltration with 2% xylocaine local anesthesia. Then, 
thermotherapy is applied to the center and active edges of the lesions until they are 
completely treated. Once this phase is finished, fusidic acid is applied for 10 days (Lopez, 
2012). 
Comparator: There are several pentavalent antimonials in the market, mainly 
sodium stibogluconate (Pentostam®) and meglumine antimoniate (Glucantime®), which 
are similar and only vary in antimony content (PAHO, 2013). In Colombia, Glucantime is 
the recommended first-line treatment. 
Outcomes: The primary outcome was DALYs averted, and the secondary was the 
number of patients cured. Cure was defined as the disappearance or re-epithelialization of 
the lesions, complete loss of induration or flattening of the lesion, and disappearance of 
lymphangitis or adenitis up to three months after the end of treatment, without reactivation 
of the lesion or the appearance of new lesions or mucosal involvement six months post 
treatment (PAHO, 2013). 
One DALY corresponds to one year of healthy life lost due to premature death, 
measuring the disease burden for specific causes. It provides a general and specific view of 
the health status of a population, helping to "make decisions and comparisons, prioritize 
resources, and implement follow-up in the health system" (Peñaloza, 2014). In its 
calculation, the following components are taken into account: i) life expectancy, which, 
according to the recommendation of previous studies of disease burden in Colombia, 
corresponds to 80 years for men and 82.5 for women; ii) the age weight, with which the 
years of healthy life of the young are valued more by having greater productive capacity; 
iii) the disability weight, which relates the specific disability of the disease during its course 
and the time lost by mortality, which is zero for ideal health states and one for states 
comparable to death; and (iv) the discount rate, which gives greater importance to current 
benefits, compared to future benefits (Peñaloza R, 2014). 
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To calculate DALYs, the years of life lost (YLL) due to premature death are 
combined with the years lived with disability (YLD) due to a disease with a given severity 
and duration, based on the following statistics quoted from the study by Martínez (2015), 
which are simultaneously based on WHO reports (Murray, 1996; Martinez, 2015; WHO, 
2016): 
YLL = KCerA/(r+β)2 {e- (r+β)(L+A)[-(r+β)(L+A)-1] – e- (r+β)A [-(r+β)A-1]}+[(1-
K)/r](1-e-rL) 
YLD = DKCerAs/(r+β) 2 {e- (r+β)(Ld+As)[-(r+β)(Ld+As)-1] –e- (r+β)As [-(r+β)As -
1]}+[(1-K)/r] (1-e -rLd) 
DALYs were estimated in an Excel spreadsheet from the WHO Global Burden of 
Disease (2016) study, with the following data taken from the National Public Health 
Surveillance System (Sistema Nacional de Vigilancia en Salud Pública–SIVIGILA) and 
studies on disease burden in Colombia in 2005 and 2010 (Acosta, 2008; National Institute 
of Health of Colombia, 2016; Peñaloza, 2014): 
K = 0.5. Age-weighting factor (0 = no age weights; 1 = full age weights). 
β = 0.04. Age-weighting parameter. 
r = 0.03. Discount rate for the years of life by time preference. 
C = 0.1658. Model constant, standard age weighting 
A: Age of the patient who died from leishmaniasis, corresponding to one woman in the age 
group between 70 and 74 years and four men in the age groups of 0-4, 30-34, 45-49, and over 80 
years old. 
L: Life expectancy. Men 80; women 82.5 years. 
D: Disability weight. According to the WHO recommendation, D is 0.022875 for patients 
with cutaneous leishmaniasis of all age groups treated and untreated. 
As: Age of the patient at the time of the disease, by estimating the percentage distribution 
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by age group and sex of incident cases of cutaneous leishmaniasis in Colombia and the average age 
of each age group. 
Ld: Duration of the event. According to the Colombian disease burden studies, for the age 
groups of 0-4, 5-14, 15-29, 30-44, 45-59, 60-69, 70-79, and over 80 years of age, the following 
durations are found: 1.2, 10.4, 23.2, 36.5, 51.1, 64.6, 74.6, and 91.7, respectively (Acosta, 2008; 
SIVIGILIA, 2016, Peñaloza, 2014). 
Time horizon: One year, corresponding to the time window in which incident cases 
of morbidity and mortality due to this disease were recorded. In addition, it is sufficient 
time for the evaluation of the outcomes of interest because DALYs take into account 
morbidity and mortality due to leishmaniasis in one year and cure is defined based on a 
follow-up of six months. Given this time horizon, no discount rate was applied. 
Resources: A cost per patient expressed in US dollars was determined and validated 
by five experts (three doctors and two dermatologists who handle this type of patient) in the 
phases of identification, measurement, and evaluation. In the identification phase, the direct 
cost-generating events described in the management guides and by the experts were 
identified, including the costs of applying the intervention (medication, doctor, and nurse), 
the use of diagnostic aids, and the management of local and systemic side effects. In the 
measurement phase, the quantity and frequency of use of each identified cost were 
established. The evaluation phase included data from the standardized tariff manuals for 
Colombia such as Traffic Accident Mandatory Insurance (SOAT) and the Drug Pricing 
Information System (SISMED), although it should be noted that the monetary results do 
not correspond to costs but only to tariffs or rates that have been agreed upon for the 
provision of health services in Colombia. 
Sources of information: The number of incident cases was taken from official 
SIVIGILA records. The probabilities of cure and therapeutic failure as well as local or 
systemic adverse events were taken from a phase III controlled clinical trial conducted in 
Colombia to assess the efficacy of thermotherapy and from one meta-analysis that 
evaluated the therapeutic efficacy of thermotherapy in cutaneous Leishmaniasis (López, 
2012; Cardona, 2015). 
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Description of the decision model: A decision tree was constructed whose initial 
node explains the two alternatives compared and includes the following states: 
1. Cure or therapeutic failure, the latter including persistence of the lesion, 
incomplete epithelization, induration, mucosal involvement, or recovery of the lesion six 
months after the end of treatment. 
2. According to therapeutic safety data, the second condition includes cure 
without adverse effects or with local or systemic effects. Adverse events were classified 
according to the "Common Terminology Criteria for Adverse Events (CTCAE) v.3" into 
local events such as pain, burning, pruritus, erythema, edema, and inflammation at the site 
of administration and systemic events such as laboratory abnormalities in complete blood 
count, blood chemistry, and in liver, kidney, or pancreatic function tests (Trotti, 2003). 
3. In case of therapeutic failure, rescue treatment was applied with pentavalent 
antimonials, in which there are two possibilities, cure or therapeutic failure. 
4. In the fourth state, the safety analysis of rescue treatment was added, 
including the three possibilities described in the second state. 
No additional states were included for the subgroup that would require a second 
rescue treatment because their probability tended to be zero, nor was death taken as a final 
outcome due to the low mortality rate of cutaneous leishmaniasis in Colombia (0.006%). 
Model assumptions: The patients adhere to treatment (no abandonment), and all of 
them receive rescue treatment in case of therapeutic failure. The patients had not received 
other therapies for the disease three months before starting treatment. At the beginning of 
the treatment regimen, the patients did not present renal or hepatic failure, hematologic 
disorders, or comorbidities. The lesions had to be less than 10 per patient and at sites far 
from the nasal or oral mucosa, eyes, and anal or urogenital orifices. It should be clarified 
that these assumptions represent the characteristics of the majority of patients in the country 
and must be considered because the type of information recorded by SIVIGILA does not 
allow subgroup analysis. 
10 
Cost-effectiveness analysis: The cost-effectiveness ratio is expressed in terms of 
the cost per DALY averted and patient cured in both alternatives. Incremental cost-
effectiveness was used to estimate the cost per DALY averted or additional patient cured in 
the treatment with thermotherapy, compared to the use of Glucantime. 
 
Incremental Cost 
Effectiveness Ratio (ICER)  
= 
Δ
C 
= 
Cost of Thermotherapy - Cost of Glucantime 
Δ
E 
DALYs averted with Thermotherapy - DALYs averted with 
Glucantime 
Sensitivity analysis: The uncertainty derived from the components of the decision 
model was evaluated using one-way deterministic analysis with tornado diagrams to 
evaluate the effect of changes in cure probabilities, costs, DALYs averted, and the number 
of patients cured. In addition, probabilistic sensitivity analysis was performed using Monte 
Carlo simulations including microsimulation of 1,000 people, an acceptability curve for 
different thresholds or willingness to pay, and the net monetary benefit. The thresholds 
recommended by the WHO (Tan-Torres, 2003) were included, according to which a health 
technology is considered highly cost-effective for values less than a certain gross domestic 
product (GDP)/per capita (US$ 6,056 for Colombia) and cost-effective for values less than 
three GDP/per capita. 
For sensitivity analysis, it was assumed that probabilities have a β (beta) distribution 
in a narrow range from 0 to 1, whereas costs, DALYs averted, and the number of patients 
cured follows a γ (gamma) distribution that can take any value greater than zero. The limits 
of the confidence intervals of efficacy (cure and therapeutic failure) and safety (local and 
systemic adverse events) of previous clinical trials were taken as measures of variability 
(López, 2012; Cardona, 2015). Regarding costs, a dispersion of 30% was taken, 
corresponding to the variability of tariffs used in contracting health services in Colombia; 
thus, the results presented are in line with the reality of payment and contracting of the 
country, where a relative variation of 20% was applied in the case of DALYs and patients 
cured. 
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Results 
Figure 1 shows decision tree for evaluating the cost-effectiveness of thermotherapy, 
compared to Glucantime, for the treatment of cutaneous leishmaniasis in Colombia (Costs 
and DALYs averted per treated patient), which shows the main health-state transition 
probabilities as well as the costs and adverse effects (DALYs). 
Table 1 describes the costs that have been identified, measured, and evaluated. In 
patients receiving thermotherapy, the cost of the intervention is US$ 501,621; the handling 
of local adverse effects, US$ 20,255; and systemic events, US$ 8,969. In patients who 
present therapeutic failure and receive rescue treatment based on pentavalent antimonials, 
the costs of their administration and use of diagnostic means to monitor local and systemic 
effects total US$ 300,053. The total cost of Glucantime administration in patients is US$ 
2,731,276; the cost for the management of local effects is US$ 25,930; for systemic effects, 
US$ 32,324; and for therapeutic failures, US$ 406,298. 
Table 1. Standard Cost for Thermotherapy and Glucantime 
 Item Frequency Cost per unit 
Thermotherapy 
ThermoMed (cryo) 1 14.04 
Medical Consultation 5 7.73 
Nurse (cures) 2 4.57 
Glucantime 
Glucantime 70 1.47 
Nurse (cures) 20 4.57 
Medical Consultation 4 7.73 
Creatinine 3 3.61 
BUN 3 2.58 
AST/ALT 3 11.21 
Amylase 3 4.19 
HLG 3 9.34 
ECG 1 10.56 
Local effects Myalgia 1 0.44 
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Arthralgia 1 0.44 
Headache 1 0.44 
Abdominal Pain 1 1.10 
Fever 1 0.44 
Vomiting, Nausea, Anorexia, Diarrhea 1 1.70 
Infection of the Lesion 1 27.44 
Systemic effects 
Renal 1 6.18 
Pancreatic 1 4.19 
Hepatic 1 11.21 
Hematological 1 9.34 
1 US Dollar = 3,051 Colombian pesos (average value for 2016). 
 
By disaggregating the costs for each of the model transition states, in the case of 
thermotherapy, it is found that the cost is US$ 142 per patient cured; if thermotherapy fails 
and rescue treatment is needed, then the cost amounts to US$ 655, and if a second rescue 
treatment is needed, then the cost would increase to US$ 2,192. It should be noted that 
these values include the costs inherent to the management of adverse effects in each state. 
In patients treated with Glucantime, under the same conditions, the costs would be US$ 
229, US$ 915, and US$ 2,973, respectively. 
Regarding effectiveness, in patients treated with thermotherapy, there were 149.0 
DALYs that were caused to a great extent by the years of life lost in patients receiving a 
second rescue treatment with pentavalent antimonials, those having systemic adverse 
effects (patients in this group are at highest risk of dying, particularly if they are at the 
extremes of life or present diseases related to immunosuppression), and those with general 
disability that depend to a large extent on incident cases. In the Glucantime group, there 
were 195.6 DALYs explained to a great extent by the component of years of life lost by the 
group of patients with systemic adverse effects and the disability component due to the 
cumulative incidence (Table 2). 
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Table 2. DALYs of the Clinical States of the Decision Model 
State of the decision model Thermotherapy Glucantime 
N YL
L 
YLD DAL
Y 
N YL
L 
YL
D 
DAL
Y 
Cure after initial treatment         
Without adverse effects 4413 0.0 55.2 55.2 1793 0.0 22.4 22.4 
Local effects 519 0.0 6.5 6.5 3724 0.0 46.6 46.6 
Systemic effects 260 0.0 3.3 3.3 1379 46.5 17.2 63.7 
Cure with rescue treatment I         
Without adverse effects 645 0.0 8.1 8.01 285 0.0 3.6 3.6 
Local effects 1341 0.0 16.8 16.8 591 0.0 7.4 7.4 
Systemic effects 497 0.0 6.2 6.2 219 35.9 2.7 38.6 
Cure with rescue treatment II         
Without adverse effects 108 0.0 1.4 1.4 30 0.0 0.4 0.4 
Local effects 225 0.0 2.8 2.8 62 0.0 0.8 0.8 
Systemic effects 83 35.9 1.0 36.9 23 11.5 0.3 11.8 
Failure with rescue treatment II         
Failure + Adverse effects 22 11.5 0.3 11.8 6 0.0 0.1 0.1 
 
Based on the DALYs shown in Table 2, the number of DALYs averted was 
calculated for each component of the model, which were then used for cost-effectiveness 
analysis (Figure 2. Cost-effectiveness plane (costs vs. DALYS averted) for thermotherapy 
and Glucantime). It should be noted that the behavior shown in Figure 2 was similar to that 
found for the secondary outcome (number of patients cured). 
The cost-effectiveness of thermotherapy was US$ 2,062 per DALY averted and US$ 
69 per patient cured. For Glucantime, it was $ 4,241 per DALY averted and US$ 85 per 
patient cured. The incremental cost-effectiveness ratio showed that thermotherapy would 
result in savings of US$ 10,534 for each additional DALY averted compared to Glucantime 
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and that each additional patient cured would cost US$ 115 (Table 3). 
 
Table 3. Cost-effectiveness Analysis of Thermotherapy vs. Glucantime  
Strategy C IC E: IE IC/IE Dominance CEA 
DALYs averted       
Thermotherapy 290,187 -- 140.75  -- -- 2,062 
Glucantime 508,797 218,935 119.99 -
20.75 
-10,534 Dominant 4,241 
Patients Cured       
Thermotherapy 290,390 -- 4,124 -- -- -- 69 
Glucantime 509,184 218,794 6,016 1,892 115 -- 85 
C: Cost. IC: Incremental cost. E: Effectiveness. IE: Incremental effectiveness. CEA: Cost effectiveness 
average. 
 
The deterministic sensitivity analysis shows that the parameters that incorporate 
greater uncertainty in the incremental cost-effectiveness ratio are the change in the 
probability of cure with thermotherapy for DALYs averted and the cost of Glucantime for 
the number of patients cured. It is worth stating that thermotherapy would be cost-effective 
in all scenarios, considering its threshold of three times the Colombian GDP per capita. 
Given the highest effectiveness of thermotherapy, the ICER indicates that this treatment 
would avoid the expenses of US$ 64,108 per additional DALY averted, compared to the 
administration of Glucantime (the dominant strategy due to having lower cost and more 
effectiveness). Even if the highest effectiveness achieved by Glucantime were to be 
considered, it is estimated that thermotherapy would imply expenses of US$ 6,675 per 
additional DALY averted; that is, even in the worse scenario, thermotherapy is highly cost 
effective (Figure 3. Deterministic sensitivity analysis tornado diagram). 
The acceptability curve from the probabilistic sensitivity analysis for DALYs 
averted shows that, independent of the willingness to pay, thermotherapy is more cost-
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effective, proving that it is a dominant strategy. The study of incremental cost-effectiveness 
shows that the majority of the simulated cases remain in quadrants I and IV. In the selection 
of the optimal strategy, with a willingness to pay of US$ 33 (100,000 Colombian pesos), 
thermotherapy is more cost-effective in 67.9% of the simulated cases, and if willingness to 
pay increases up to US$ 294 (900,000 Colombian pesos), then the same conclusion is 
reached in 86.1% of cases (Figure 4. Sensitivity analysis by acceptability curve, 
incremental cost-effectiveness with threshold, and optimal strategy with 10,000 Monte 
Carlo simulations). For the number of patients cured, thermotherapy is identified as the 
optimal strategy in 68.2% of cases, using a threshold of US$ 300,000. 
Figure 5 shows net monetary benefit of thermotherapy and Glucantime for DALYs 
averted in cutaneous leishmaniasis according to different levels of willingness to pay. Even 
with different levels of willingness to pay, thermotherapy remains the strategy with the 
greatest net monetary benefit. 
Finally, Table 4 shows the proportion of simulated cases in each of the quadrants of 
the cost effectiveness plan, highlighting that, for DALYs averted, thermotherapy is 
dominant in 67.9% of cases and cost-effective in 18.2% of cases, with an incremental cost-
effectiveness ratio of less than US$ 300, whereas for the proportion of patients cured, it is 
cost-effective in 72% of cases. 
 
Table 4. Probabilistic Sensitivity Analysis Using 1,000 Monte Carlo Simulations 
Component Quadrant IE IC ICER % DALYs % Cured 
C1 IV >0 <0 Superior 67.9 0.0 
C2 I >0 >0 <1.0 18.2 72.0 
C3 III <0 <0 >1.0 0.0 0.0 
C4 I >0 >0 >1.0 0.0 12.8 
C5 III <0 <0 <1.0 0.0 1.4 
C6 II <0 >0 Inferior 13.9 13.8 
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Indifferent Origin =0 =0 0/0 0.0 0.0 
 
Discussion 
This the first study in the scientific literature that presents a cost-effectiveness 
analysis of thermotherapy for the treatment of cutaneous leishmaniasis, obtaining favorable 
results and a high level of evidence for patients in Colombia, given that the efficacy and 
safety data of comparative alternatives were taken from phase IIb and III controlled clinical 
trials with infected patients from this country. In addition, the findings from this study will 
have a high potential for extrapolation to populations with similar eco-epidemiological, 
clinical, and parasitological conditions. 
The evidence presented adds to other previous publications, concluding that 
thermotherapy can be applied in patients with cutaneous leishmaniasis, to the extent that its 
therapeutic efficacy is similar to that of pentavalent antimonials, although with a lower 
proportion of adverse effects (Cardona, 2015). This is more relevant, considering some 
practical advantages of thermotherapy, such as shorter duration, better compliance, and the 
fact that it does not require paraclinical examinations and is able to be used in patients with 
renal, hepatic, or cardiac disorders, pregnant women, children, and other groups in which 
pentavalent antimonials or miltefosine are contraindicated (Safi, 2012; López, 2013). 
From an economic perspective, it should be considered that comprehensive 
economic evaluations of this disease are scarce, and none has evaluated local or physical 
treatments such as thermotherapy, which makes it difficult to compare the results found 
with those reported in previous publications. However, it is important to indicate the cost 
per DALY averted for other interventions implemented to treat this disease. In this sense, 
Reithinger’s study in Afghanistan reported that intralesional and intramuscular 
administration of antimonials generated a cost of US$ 27 per patient cured and US$ 1,200 
per DALY averted (Reithinger, 2007), which is significantly lower than the results of the 
present study and could be explained by the low cost of these drugs in Asian countries 
compared to South America. 
17 
For its part, the Orellano group in Argentina found an ICER of US$ 156 per DALY 
averted for an early diagnosis strategy and US$ 13,155 for the use of insecticide-
impregnated clothing and curtains (Orellano, 2013), which is higher than the alternative 
evaluated in this study and would constitute an important antecedent for designing 
subsequent cost-effectiveness studies that would allow the purchase of various disease 
interventions to determine whether vector control, timely diagnosis, conventional treatment, 
or new local and physical treatments are more or less cost-effective. 
In two studies conducted in Colombia, it has been reported that the cost is US$ 345 
per patient treated and cured with antimonials and US$ 15,215 per DALY averted during an 
outbreak of the disease (Vega, 2007); in contrast, the evaluation of treatments included in 
the disease management guide in Colombia found that the incremental cost varies between 
US$ 10,000 and US$ 14,500 per DALY averted and between US$ 1,000 and US$ 1,500 per 
patient cured (Niño, 2014). The differences found with respect to the current study could be 
based on three uncontrolled sources of uncertainty in the sensitivity analysis. The first 
difference would correspond to structural uncertainty, given that one of the studies cited 
used a Markov model in which infection relapse was not included as a therapeutic failure 
and the time horizon was higher than indicated to determine patient cure. The second would 
be a source of methodological uncertainty to the extent that some data from the Niño study 
were taken from phase II clinical trials or there were methodological quality problems. 
Finally, divergences between studies could also be due to the heterogeneity of the 
populations evaluated. 
It should be borne in mind that the treatment of cutaneous leishmaniasis presents 
large cost variations related to the application protocol (intralesional or intramuscular), type 
of patient care, and health regimen, which should be considered in the uncertainty analysis. 
In addition, it is worth noting that studies that have recommended the use of pentavalent 
antimonials due to their low cost generally do not include the costs associated with the 
management of adverse effects (Reithinger, 2007; Vanlerberghe, 2007). 
On the other hand, it is appropriate to state some of the reasons that have led to an 
increase in the use of cost-effectiveness analysis at present, i.e., the need (i) to prioritize 
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funding for interventions, reduce health inequities, and address the well-being of future 
generations; (ii) to identify the best method of allocating health resources or optimizing the 
health budget; (iii) to avoid or transform inefficiencies that are present in many countries 
for the improvement of health states and to enact health policy, particularly in poor or 
middle-income countries, based on the costs and effects of different health interventions; 
and (v) to improve clinical practice guidelines (Tan-Torres, 2003). 
Several limitations of this type of economic evaluation should also be considered, 
such as the type of cost items to be included, the extra costs incurred due to the years of life 
gained by an intervention, the variability in the manner in which interventions are 
implemented in different contexts or regions, and the assessment of the null effect when 
health processes are interrelated, among others (Tan-Torres, 2003). The main limitation of 
this study is the fact that it was not possible to perform subgroup analysis because 
SIVIGILA records are deficient in the description of incident cases – according to some 
relevant characteristics for the estimation of cost-effectiveness – such as the infecting 
species and the number, size, type, and location of the lesions. 
Consistent with the above, further studies should improve subgroup analysis and the 
integration of costs from the social perspective, considering that treatment with pentavalent 
antimonials generates higher costs related to transportation to the place of treatment, out-of-
pocket costs to pay for outpatient services, indirect costs related to the loss of productive 
activities of patients and their families, etc. These costs are greater compared to 
thermotherapy, given that treatment with pentavalent antimonials requires more medical 
visits, bearing higher social costs related to the treatment itself and the management of 
adverse effects. 
 
Conclusion: Thermotherapy is a highly cost-effective strategy for the treatment of 
cutaneous leishmaniasis in Colombia. Its incorporation into clinical practice guidelines and 
public health programs could represent savings of approximately US$ 10,500 per additional 
DALY averted and the cost of US$ 115 per additional patient cured, compared to the use of 
Glucantime. This evidence adds to previous findings that have demonstrated the multiple 
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benefits of this treatment alternative, such as better patient compliance, the simplicity of 
application, safety, and low costs. This is consistent with the objectives of the WHO, the 
Drugs for Neglected Diseases Initiative (DNDi), and other entities that seek to promote 
research on new drugs for this disease. This study will also help in guiding health policy 
actions for the management of this disease in Colombia and other countries with similar 
parasitological, clinical, and epidemiological patterns. 
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